Nanoparticles that turn inflammation into propulsion power deliver targeted IBD treatment, enhancing precision and efficacy.
Abu Dhabi, UAE: Sheikh Shakhbout Medical City (SSMC), one of the UAE’s largest hospitals for serious and complex care and a ...
P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis," published in the November 2024 issue of Gastroenterology by Hu et al. Since 2015, CT-P13, a ...
Not everyone responds equally well to treatments for inflammatory bowel disease (IBD). What will work for individual patients involves trial and error during the treatment process.
Not everyone responds equally well to treatments for inflammatory bowel disease (IBD). What will work for individual patients involves trial and error during the ...
Not everyone responds equally well to treatments for inflammatory bowel disease (IBD). What will work for individual patients involves trial and error ...
Not everyone responds equally well to treatments for inflammatory bowel disease (IBD). What will work for individual patients ...
A randomized controlled trial finds no clear benefit of adding bezlotoxumab to FMT in patients with IBD and recurrent C difficile infection.
Subsequent treatment should be initiated that is evidence-based ... grant (1S06023N); Fonds Wetenschappelijk Onderzoek, and ...
The underlying cause of inflammatory bowel disease (Crohn’s and ulcerative colitis) still isn’t well-understood. Although ...